SMITH & NEPHEW PLC Inactive Instrument
Smith & Nephew plc Stock Berne S.E.
Equities
SN.
GB0009223206
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 5.81B 5.2B | Sales 2025 * | 6.12B 5.48B | Capitalization | 11.8B 10.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 526M 471M | Net income 2025 * | 687M 615M | EV / Sales 2024 * | 2.48 x |
| Net Debt 2024 * | 2.61B 2.34B | Net Debt 2025 * | 2.3B 2.06B | EV / Sales 2025 * | 2.3 x |
| P/E ratio 2024 * |
21.3
x | P/E ratio 2025 * |
16.1
x | Employees | 18,452 |
| Yield 2024 * |
2.76% | Yield 2025 * |
3.09% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew plc
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +12.62% | 128B | |
| +53.19% | 6.65B | |
| -23.60% | 6.65B | |
| -30.75% | 4.19B | |
| -19.96% | 2.46B | |
| -17.14% | 1.94B | |
| -21.05% | 1.75B | |
| -37.13% | 1.45B | |
| -16.31% | 1.06B |
